Translation and validation of BPHQ derived from PRIME-MD: A multi-centric research project(Pfizer)
A study of the effect of LY2216684, a Selective Nor-epinephrine Reuptake Inhibitor (NERI), in the treatment of major depression.
A phase III randomised placebo control A phase III randomized, placebo-controlled, double-dummy study evaluating the safety and efficacy of oral ziprasidone vs haloperiodol and placebo in in-patients with acute manic episode (Pfizer)
Drug Trial-EMD 16, 923- an anxiolytic drug ( E. Merck)
A double blind, multi-centric, parallel group comparison of the efficacy and safety of ziprasidone and chlorpromazine in patients with schizophrenia who are refractory to standard therapy. (Pfizer).
Efficacy and safety of olanzapine versus haloperidol in schizophrenic patients in India. (Eli Lilly).
A prospective randomized, double-blind, placebo-controlled study of the effectiveness and safety of Risperdal Consta augmentation in adult patients with frequently-relapsing bipolar disorder ( Janssen Medical Affairs)
Dr Shubh Mohan Singh Associate Professor Psychiatry
Dr Subodh BN Associate Professor Psychiatry
Dr Susanta Kumar Padhy Associate Professor Psychiatry
Dr Ruchita Shah Assistant Professor Psychiatry
Dr. Akhilesh Sharma Assistant Professor Psychiatry
Prof. N.N. Wig
Prof. V.K. Varma
Prof. P. Kulhara
Prof. Savita Malhotra
Dr. S.K. Verma
One of the major influences in my training as a psychiatrist was that of Dr. Robert A. Moore of the University of Michigan, USA. He was the Director of Residency Training while I trained there (1963-65).